PhD - Sam Rothstein brings more than 12 years of experience in the design of complex drug products and has led $4 million of Small Business Innovation Research grants on their development. Prior to founding Duo Oncology, Dr. Rothstein began working at the interface of cancer therapy and drug delivery as the CEO of Qrono Inc in 2017. Since joining industry in 2012, Dr. Rothstein has brought three complex drug products into IND-enabling studies.

PharmD, PhD - Katherine Eichinger is a licensed pharmacist with a master’s degree in clinical research and a doctorate in pharmaceutical science. Her experience bridges from fundamental bench research to clinical studies and includes operations experience from two major hospital systems. She has more than 10 years in preclinical research and authored eleven publications advancing science in drug pharmacology, immunology, and human disease.

PhD - Jingjing Sun has more than 10 years of experience developing nanoformulations for cancer therapy, including Duo Oncology's lead product. She is an inventor of 7 issued/pending patents in this field. She has also published one book chapter and 35 peer-reviewed papers in top journals. Dr. Sun is an Research Assistant Professor in Department of Pharmaceutical Sciences, University of Pittsburgh where she also completed a post doc.

Deal Memo and Term Sheet posted on box
https://app.box.com/s/iwwymlxhn7ofe3r6cm43stwcj2vrtfnr
Please contact Joe Gatto (joe@seedfolio.vc) for due diligence findings.